Last reviewed · How we verify
NCT07071610
A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis
Phase 2 trial testing LNK01004 ointment 0.3% in Atopic Dermatitis in 75 participants. Completed in 24 July 2025.
24 July 2025
Quick facts
| Lead sponsor | Lynk Pharmaceuticals Co., Ltd |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 75 |
| Start date | 18 March 2025 |
| Primary completion | 24 July 2025 |
| Estimated completion | 24 July 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- LNK01004 ointment 0.3% — full drug profile →
- LNK01004 ointment 1.0% — full drug profile →
- Vehicle
Conditions studied
- Atopic Dermatitis — all drugs for Atopic Dermatitis →
Sponsor
Lynk Pharmaceuticals Co., Ltd — full company profile →
Who can join
Adults 18 to 65, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the efficacy and safety of two concentrations (0.3 percent \[%\] and 1%) of twice daily LNK01004 ointment for the topical treatment in adult subjects with atopic dermatitis. This is a multicenter, randomized, double-blind, vehicle-controlled, 3-arm, parallel-group, dose-finding study in adult subjects with atopic dermatitis. Two concentrations of LNK01004 ointment (0.3% and 1%) and a vehicle control ointment will be equally randomized and evaluated following application to all atopic dermatitis lesions (except on the scalp) twice daily (morning and evening) for 8 weeks. This study will consist of 3 periods: up to 4 weeks screening, 8 weeks double-blind treatment, and 2 weeks post-treatment follow-up. Approximately 75 subjects (25 subjects for each group) with moderate to severe AD will be enrolled overall.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07071610
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of LNK01004 ointment 0.3%
Trials testing the same drug.
- NCT06553287 — Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis. · Phase 1 · completed
Other recruiting trials for Atopic Dermatitis
Currently open trials in the same condition.
- NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
- NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
- NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
- NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
- NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
Other Lynk Pharmaceuticals Co., Ltd trials
Trials by the same sponsor.
- NCT06277245 — A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis. · Phase 3 · completed
- NCT06276998 — A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA) · Phase 3 · active not recruiting
- NCT06553287 — Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis. · Phase 1 · completed
- NCT06085521 — A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis · Phase 2 · completed
- NCT06085534 — A Study of LNK01001 Capsule in Patients With Ankylosing Spondylitis · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07071610 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lynk Pharmaceuticals Co., Ltd
- Last refreshed: 14 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07071610.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing